Skip to main content
SpringerLink
Log in

Le panitumumab (Vectibix®) en oncologie digestive: quel rationnel pharmacologique et pharmacocinétique ?

Panitumumab (Vectibix®) in digestive oncology: pharmacological and pharmacokinetic rationale

  • Mise au Point / Update
  • Published:
Oncologie

Abstract

The rise of target therapies is a new hope in digestive oncology, including for treating metastatic colorectal cancer. Constant improvement in response and survival have been achieved, since the introduction of 5-fluorouracil as a single agent several decades ago, through the development of new cytotoxics such as irinotecan or oxaliplatin, or more recently with the era of biologics (e.g., bevacizumab or cetuximab). Panitumumab is a new 100%-human monoclonal antibody that targets the extracellular domain of the EGFR- 1 receptor. Because its mechanism of action is similar to that of cetuximab, chosing the best biologics to be used could be therefore an uneasy task. This review covers panitumumab’s pharmacodynamic and pharmacokinetic characteristics, a new target therapy that could be an attractive therapeutic option in digestive oncology.

Résumé

L’avènement des thérapies ciblées a profondémentmodifié la stratégie de prise en charge chimiothérapeutique des cancers digestifs. La mise à disposition du clinicien de biothérapies innovantes comme les anticorps monoclonaux anti-VEGF (bevacizumab) ou anti-EGFR (cetuximab) a ouvert denouvellesperspectives entermes d’amélioration de la réponse et d’impact sur la survie globale ou sans progression chez les patients atteints de cancers digestifs, au premier rang desquels le cancer colorectal métastatique. Le panitumumab est un nouvel anticorps anti-EGFR1 (Her1) qui a reçu son autorisation de mise sur le marché dans le cancer colorectal métastatique chez les patients K-Ras WT et exprimant EGFR après échec des chimiothérapies standard. Nous allons passer en revue les caractéristiques pharmacologiques et pharmacocinétiques du panitumumab qui peuvent être autant d’éléments pour un rationnel d’utilisation de ce nouvel anticorps monoclonal en oncologie digestive.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Références

  1. Amado RG, Wolf M, Peeters M, et al. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626–1634

    Article  CAS  PubMed  Google Scholar 

  2. Asmis T, Shah M, Haviland D, et al. (2008) Panitumumab with or without chemotherapy in metastatic colorectal cancer (mCRC): safety and unusual activity, even following progression on cetuximab. ASCO Gastrointestinal Cancers Symposium, Abstract

  3. Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28: 1254–1261

    Article  CAS  PubMed  Google Scholar 

  4. Berlin J (2007) ASCO Annual Meeting Proceedings Vol 25, noo18S (June 20 Supplement) 2007

  5. Beum PV, Mack DA, Pawluczkowycz AW, et al. (2008) Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol 181: 8120–8132

    CAS  PubMed  Google Scholar 

  6. Chung CH, Mirakhur B, Chan E, et al. (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358: 1109–1117

    Article  CAS  PubMed  Google Scholar 

  7. Cunningham D, Humblet Y, Siena S, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 51: 337–345

    Article  Google Scholar 

  8. De Roock W, Claes B, Bernasconi D, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CAmutations on the efficacy of cetuximab plus chemotherapy in chemotherapyrefractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (Epub ahead of print)

  9. Di Nicolantonio F, Martini M, Molinari F, et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26(35): 5668–5670

    Article  Google Scholar 

  10. Doi T, Ohtsu A, Tahara M, et al. (2009) Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors. Int J Clin Oncol 14: 307–314

    Article  CAS  PubMed  Google Scholar 

  11. Foley KA, Wang PF, Barber BL, et al. (2010) Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. Ann Oncol (Epub ahead of print)

  12. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186

    Article  CAS  PubMed  Google Scholar 

  13. Giannopoulou E, Antonacopoulou A, Matsouka P, et al. (2009) Autophagy: novel action of panitumumab in colon cancer. Anticancer Res 29: 5077–5082

    CAS  PubMed  Google Scholar 

  14. Hansen NL, Chandiramani DV, Morse MA, et al. (2010) Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center. J Oncol Pharm Pract (Epub ahead of print)

  15. Hecht JR, Patnaik A, Berlin J, et al. (2007) Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110: 980–988

    Article  CAS  PubMed  Google Scholar 

  16. http://clinicaltrials.gov/ct2/showNCT00842257

  17. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. (2005) Panitumumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502–3508

    Article  CAS  PubMed  Google Scholar 

  18. Jakobovits A, Amado RG, Yang X, et al. (2007) From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25: 1134–1143

    Article  CAS  PubMed  Google Scholar 

  19. Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040–2048

    Article  CAS  PubMed  Google Scholar 

  20. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. (2008) KRAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757–1765

    Article  CAS  PubMed  Google Scholar 

  21. Lacouture ME, Mitchell EP, Piperdi B, et al. (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a Phase II, Open-Label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28: 1351–1357

    Article  CAS  PubMed  Google Scholar 

  22. Laurent-Puig P, Cayre A, Manceau G, et al. (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27: 5924–5930

    Article  CAS  PubMed  Google Scholar 

  23. Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93: 2645–2668

    Article  CAS  PubMed  Google Scholar 

  24. Lu JF, Bruno R, Eppler S, et al. (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62: 779–786

    Article  CAS  PubMed  Google Scholar 

  25. Lurje G, Lenz HJ (2010) EGFR signaling and drug discovery. Oncology 77: 400–410

    Article  Google Scholar 

  26. Lynch DH, Yang XD (2002) Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 29: 47–50

    Article  CAS  PubMed  Google Scholar 

  27. Ma P, Yang BB, Wang YM, et al. (2009) Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol 49: 1142–1156

    Article  CAS  PubMed  Google Scholar 

  28. Mascelli MA, Zhou H, Sweet R, et al. (2007) Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol 47: 553–565

    Article  CAS  PubMed  Google Scholar 

  29. Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369–385

    Article  CAS  PubMed  Google Scholar 

  30. Mould DR, Green B (2010) Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 24: 23–39

    Article  CAS  PubMed  Google Scholar 

  31. Peeters M, Wilson G, Ducreux M, et al. (2008) Phase III study (20050181) of panitumumab (pmab) with folfiri versus folfiri alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): pooled safety results. ASCP Meeting, Abstract 4064

  32. Power DG, Shah MA, Asmis TR, et al. (2010) Safety and efficacy of panitumumab following cetuximab: retrospective review of the memorial Sloan-Kettering experience. Invest New Drugs 28: 353–360

    Article  CAS  PubMed  Google Scholar 

  33. Price TJ, Tebbutt NC, Karapetis C et al. (2010) Current opinion on optimal treatment choices in first-line therapy for advanced or metastatic colorectal cancer: report from the Adelaide colorectal tumor group meeting; Stockholm, Sweden; September 2008. Clin Colorectal Cancer 9: 8–14

    Article  CAS  PubMed  Google Scholar 

  34. Reinacher-Schick AC, Kubicka S, Freier W et al. (2008) Activity of the combinaison of panitumumab with capecitabine-irinotecan or capecitabine-oxaliplatin in advanced colorectal cancer: a randomized phase II study of the AIO colorectal study group (AIO trial 0604). ASCO Meeting, Abstract 4030

  35. Saif MW, Peccerillo J, Potter V (2009) Successful rechallenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemother Pharmacol 63: 1017–1022

    Article  PubMed  Google Scholar 

  36. Saltz LB, Douillard JY, Pirotta N, et al. (2001) Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 6: 81–91

    Article  CAS  PubMed  Google Scholar 

  37. Sartore-Bianchi A, Moroni M, Veronese S, et al. (2007) Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25: 3238–3245

    Article  CAS  PubMed  Google Scholar 

  38. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, et al. (2010) Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 184:512–520

    Article  CAS  PubMed  Google Scholar 

  39. Siena S, Cassidy J, Tabernero J, et al. (2010) Randomized phase III study of panitumumab (pmab) with folfox4 compared to folfox4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial. ASCO Gastrointestinal Cancers Symposium, Abstract

  40. Stephenson JJ, Cohn A, Crawford J, et al. (2007) Administration of panitumumab (Pmab) every two weeks (Q2W) as a 30 or 60 minutes infusion: safety and pharmacokinetics (PK) from a phase I study in patients with solid tumors. ASCO Gastrointestinal Cancers Symposium, Orlando, Abstract 368

  41. Stephenson JJ, Gregory C, Burris H, et al. (2009) An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors. Clin Colorectal Cancer 8: 29–37

    Article  CAS  PubMed  Google Scholar 

  42. Tang L, Persky AM, Hochhaus G, et al. (2004) Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93: 2184–2204

    Article  CAS  PubMed  Google Scholar 

  43. Tournigand C, Andre T, Achille E, et al. (2004) Folfiri followed by Folfox6 or the reverse sequence in advanced colorectalcancer: a randomized GERCOR study. J Clin Oncol 22: 229–237

    Article  CAS  PubMed  Google Scholar 

  44. Van Cutsem E, Peeters M, Siena S, et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007 25: 1658–1664

    Article  Google Scholar 

  45. Van Cutsem E, Siena S, Humblet Y, et al. (2008) An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 19: 92–98

    Article  PubMed  Google Scholar 

  46. Viale PH (2010) Incorporating new data on colorectal cancer into nursing practice. Clin J Oncol Nurs 14: 92–100

    Article  PubMed  Google Scholar 

  47. Yoshino T, Muro K, Doi T, et al. (2008) Phase II study of panitumumab (Pmab) monotherapy in Japanese patients (pts) with metastatic colorectal cancer (mCRC) after the failure of fluoropyrimidine, irinotecan (CPT-11), and oxaliplatin (OHP) chemotherapy. ASCO Gastrointestinal Cancers Symposium, Abstract

  48. Zhang Y, Pastan I (2008) High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin Cancer Res 14: 7981–7986

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire de pharmacocinétique UMR-MD3, université d’Aix-Marseille et pôle oncologie, APHM, Marseille, France

    J. Ciccolini

Authors
  1. J. Ciccolini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Ciccolini.

About this article

Cite this article

Ciccolini, J. Le panitumumab (Vectibix®) en oncologie digestive: quel rationnel pharmacologique et pharmacocinétique ?. Oncologie 12, 565–571 (2010). https://doi.org/10.1007/s10269-010-1933-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-010-1933-4

Keywords

Mots clés

Search

Navigation